New Appointment: Nicolas Trouche Replaces Thomas Kuhn as CEO at Poxel
New Leadership at Poxel S.A.: Sophie Jacq Lapointe Takes the Helm
Poxel S.A., a pioneering biopharmaceutical company, has undergone significant changes in its Board of Directors. The appointments of four new directors, including Sophie Jacq Lapointe as Chairman, took effect on July 31, 2025.
Sophie Jacq Lapointe, an accomplished figure in the pharmaceutical industry with over 20 years of experience, brings her expertise in oncology, immunology, neuroscience, rare diseases, and endocrinology to the table. She has contributed to numerous commercial successes throughout her career.
Joining her on the new Board are Nicolas Trouche, who has been appointed as the new CEO, Alexandre Bragadir, and Amit Kohli. Both Nicolas Trouche and Amit Kohli are considered independent directors.
Nicolas Trouche, with his experience in technology start-ups and restructuring B2B industrial and commercial companies, will lead Poxel S.A. as its CEO. Amit Kohli, who operates at the intersection of science, finance, and commercialization, brings over 3 decades of leadership experience to the table.
Alexandre Bragadir, a Senior Investment Director at IPF Partners, a firm specialising in non-dilutive financing for innovative healthcare companies across Europe, rounds out the new board.
The appointments of Sophie Jacq Lapointe, Amit Kohli, and Alexandre Bragadir are subject to ratification at the next general meeting of shareholders of the Company.
The resignations of Pascale Boissel, Richard Kender, Thomas Kuhn, and Khoso Baluch from the Board of Directors of Poxel S.A., effective July 31, marked the end of an era. Thomas Kuhn, who had been serving as the CEO, also resigned on the same day.
These changes come as Poxel S.A. has filed for reorganization proceedings and will be subject to ratification at the next general shareholders' meeting.
With the new leadership in place, Poxel S.A. is poised to navigate the challenges ahead and continue its mission to improve the lives of patients with serious disorders by developing innovative therapies.
[1] Poxel S.A. Press Release, "Poxel S.A. Announces Change of Directors and Appointment of New CEO," July 31, 2025. [2] BusinessWire, "Poxel S.A. Announces Change of Directors and Appointment of New CEO," July 31, 2025. [3] Reuters, "Poxel S.A. Appoints Sophie Jacq Lapointe as Chairman of the Board," July 31, 2025. [4] FierceBiotech, "Poxel S.A. Names Nicolas Trouche as New CEO," July 31, 2025.
Sophie Jacq Lapointe, in her new role as Chairman, leverages her extensive expertise in various fields such as oncology, immunology, and finance to contribute to Poxel S.A.'s business strategies. The new CEO, Nicolas Trouche, with his background in technology start-ups and B2B industrial restructuring, aims to drive technological advancements within the company.
